Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

26.68USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$26.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,176
52-wk High
$43.30
52-wk Low
$23.18

Latest Key Developments (Source: Significant Developments)

Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA.THERAVANCE BIOPHARMA INC - ‍FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH U.S. FDA FOR USE OF TRELEGY ELLIPTA​.  Full Article

Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Theravance Biopharma Inc -:Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease.Theravance Biopharma Inc - ‍NDA is supported by companies' Phase 3 program for revefenacin​.  Full Article

Theravance Biopharma posts Q3 loss of $1.27 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Theravance Biopharma Inc :Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update.Q3 revenue $4.3 million versus i/b/e/s view $4.6 million.Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $434.4 million as of september 30, 2017​.Qtrly basic and diluted net loss per share $1.27‍​.  Full Article

Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Mylan Nv :Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting.Theravance Biopharma Inc - ‍remain on track to submit an NDA for Revefenacin Q4 of 2017​.Theravance Biopharma Inc - ‍results demonstrated statistically significant and clinically meaningful improvements for revefenacin over placebo ​.Theravance Biopharma Inc - ‍both doses of revefenacin had comparable rates of adverse events to placebo​.  Full Article

Theravance Biopharma Q2 revenue $5.5 million
Monday, 8 Aug 2016 

Theravance Biopharma Inc : Q2 revenue $5.5 million . Theravance Biopharma Inc reports second quarter 2016 financial results and provides business update . Q2 revenue view $12.7 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S .Qtrly loss per share $1.06.  Full Article

Theravance Biopharma posts positive results from early-stage trial of Ulcerative Colitis drug
Thursday, 9 Jun 2016 

Theravance Biopharma Inc : Reports positive results from phase 1 clinical trial of TD-1473, a GI-targeted Pan-Janus Kinase (JAK) inhibitor . Data from study demonstrated TD-1473 to be generally safe and well tolerated . There were no serious adverse events .Intends to initiate a phase 1b clinical trial of TD-1473 in patients with ulcerative colitis later in 2016.  Full Article

Takeda licenses global rights to Theravance Biopharma's TD-8954
Wednesday, 8 Jun 2016 

Theravance Biopharma Inc : Takeda Licenses Global Rights To Theravance Biopharma's Td-8954, a novel 5-HT4 agonist and motility agent for gastrointestinal motility disorders . Theravance biopharma inc says will receive an upfront cash payment of $15 million .Will be eligible to receive success based development and sales milestone payments as well as double digit royalties on worldwide net sales by takeda.  Full Article

Theravance says new data analyses from phase 3 attain trials support vibativ as a treatment for staphylococcus aureus HABP/VABP
Monday, 16 May 2016 

Theravance Biopharma Inc :New data analyses from phase 3 attain trials support Vibativ(telavancin) as a treatment for staphylococcus aureus HABP/VABP, including cases caused by MRSA.  Full Article

Theravance Biopharma Q1 revenue $18.4 mln
Monday, 9 May 2016 

Theravance Biopharma Inc : Qtrly loss per share $1.10 . Q1 earnings per share view $-0.96, revenue view $18.7 million -- Thomson Reuters I/B/E/S . Theravance biopharma, inc. Reports first quarter 2016 financial results and provides business update .Q1 revenue $18.4 million.  Full Article

Theravance Biopharma says FDA approved expanded label for vibativ
Monday, 9 May 2016 

Theravance Biopharma Inc : Theravance Biopharma says in addition, vibativ is approved in U.S. for treatment of adult patients with complicated skin & skin structure infections . Conducting phase 3 study of telavancin in primary complicated s. Aureus bacteremia, to be completed in late 2017 or early 2018 .Theravance biopharma announces fda approval of expanded label for vibativ(r) (telavancin).  Full Article

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA